Harvard's xenotransplantation technology developer eGenesis has raised a $100m in its series B round.

US-based gene editing technology developer eGenesis yesterday closed a $100m series B round that featured Leaps by Bayer, an investment vehicle for pharmaceuticals and chemicals producer Bayer. Fresenius Medical Care Ventures, the investment arm of kidney dialysis clinic operator Fresenius Medical Care, led the round, which also included Wellington Partners, Arch Venture Partners, Biomatics Capital,…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.